logo

HROW

Harrow
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
Consensus Rating "Buy"
EPS Beats Expectation
Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About HROW

Harrow, Inc.

An eyecare pharmaceutical company that developing innovative ophthalmic prescription therapies

Pharmaceutical
Invalid Date
02/08/2013
NASDAQ Stock Exchange
382
12-31
Common stock
1A Burton Hills Blvd., Suite 200, Nashville, Tennessee 37215
--
Harrow, Inc., formed in Delaware in January 2006 as Bywater Resources Corporation, is primarily involved in mineral development activities. On September 11, 2007, it was renamed Transdel Pharmaceuticals, and on December 13, 2018, it was renamed Harrow Health. The company is an ophthalmology-focused pharmaceutical company specializing in the development, production and sale of innovative medicines that provide unique competitive advantages and meet unmet needs in the market. They are committed to fulfilling the company's mission to deliver high-quality new medicines to physicians and patients at affordable prices.

Earnings Call

Company Financials

EPS

HROW has released its 2025 Q1 earnings. EPS was reported at -0.38, versus the expected 0.01, missing expectations. The chart below visualizes how HROW has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

HROW has released its 2025 Q1 earnings report, with revenue of 47.83M, reflecting a YoY change of 38.29%, and net profit of -17.78M, showing a YoY change of -31.07%. The Sankey diagram below clearly presents HROW's revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime